{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:35:01Z","timestamp":1789425301938,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":680,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003Recent trials of recombinant, live-attenuated chimeric yellow fever-dengue tetravalent dengue vaccine (CYD-TDV) demonstrated efficacy against symptomatic, virologically confirmed dengue disease with higher point estimates of efficacy toward dengue virus (DENV)3 and DENV4 and moderate levels toward DENV1 and DENV2. It is interesting to note that serotype-specific efficacy did not correlate with absolute neutralizing antibody (nAb) geometric mean titer (GMT) values measured in a Vero-based plaque reduction neutralization test assay. The absence of Fc\u03b3 receptors on Vero cells may explain this observation.<\/jats:p>\n               <jats:p>Methods. \u2003We performed parallel seroneutralization assays in Vero cells and CV-1 cells that express Fc\u03b3RIIa (CV-1-Fc) to determine the neutralizing and enhancing capacity of serotype-specific DENV Abs present in CYD-TDV clinical trial sera.<\/jats:p>\n               <jats:p>Results. \u2003Enhancement of DENV infection was observed in CV-1-Fc cells in naturally exposed nonvaccine sera, mostly for DENV3 and DENV4, at high dilutions. The CYD-TDV-vaccinated sera showed similar enhancement patterns. The CV-1-Fc nAb GMT values were 2- to 9-fold lower than Vero for all serotypes in both naturally infected individuals and CYD-TDV-vaccinated subjects with and without previous dengue immunity. The relative (CV-1-Fc\/Vero) GMT decrease for anti-DENV1 and anti-DENV2 responses was not greater than for the other serotypes.<\/jats:p>\n               <jats:p>Conclusions. \u2003In vitro neutralization assays utilizing Fc\u03b3RIIa-expressing cells provide evidence that serotype-specific Ab enhancement may not be a primary factor in the serotype-specific efficacy differences exhibited in the CYD-TDV trials.<\/jats:p>","DOI":"10.1093\/ofid\/ofv172","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T01:28:42Z","timestamp":1447378122000},"source":"Crossref","is-referenced-by-count":12,"title":["Influence of Fc\u03b3RIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine"],"prefix":"10.1093","volume":"2","author":[{"given":"Anthony M.","family":"Byers","sequence":"first","affiliation":[{"name":"Sanofi Pasteur, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Broder","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Haupfear","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana M.","family":"Timiryasova","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Swiftwater, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branda T.","family":"Hu","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Swiftwater, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boaz","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Swiftwater, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Warren","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Jackson","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Moser","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guy","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"2020081009465013200_OFV172C1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2020081009465013200_OFV172C2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0140-6736(02)09522-3","article-title":"Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever","volume":"360","author":"Kochel","year":"2002","journal-title":"Lancet"},{"key":"2020081009465013200_OFV172C3","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1128\/JVI.00316-08","article-title":"Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II","volume":"82","author":"Lai","year":"2008","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.239.4839.476","article-title":"Pathogenesis of dengue: challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science"},{"key":"2020081009465013200_OFV172C5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.01826-10","article-title":"An in-depth analysis of original antigenic sin in dengue virus infection","volume":"85","author":"Midgley","year":"2011","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.1990.42.179","article-title":"Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study","volume":"42","author":"Guzman","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"2020081009465013200_OFV172C7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/infdis\/128.1.15","article-title":"Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection","volume":"128","author":"Halstead","year":"1973","journal-title":"J Infect Dis"},{"key":"2020081009465013200_OFV172C8","first-page":"83","article-title":"Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis","volume":"338","author":"Rothman","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"2020081009465013200_OFV172C9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/oxfordjournals.aje.a113932","article-title":"Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak","volume":"120","author":"Sangkawibha","year":"1984","journal-title":"Am J Epidemiol"},{"key":"2020081009465013200_OFV172C10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"Halstead","year":"1977","journal-title":"Nature"},{"key":"2020081009465013200_OFV172C11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4269\/ajtmh.1989.40.444","article-title":"Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever","volume":"40","author":"Kliks","year":"1989","journal-title":"Am J Trop Med Hyg"},{"key":"2020081009465013200_OFV172C12","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1099\/0022-1317-71-12-2909","article-title":"Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies","volume":"71","author":"Morens","year":"1990","journal-title":"J Gen Virol"},{"key":"2020081009465013200_OFV172C13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"2020081009465013200_OFV172C14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"2020081009465013200_OFV172C15","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1128\/JVI.68.7.4572-4579.1994","article-title":"Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system","volume":"68","author":"Baldinotti","year":"1994","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/QAD.0b013e32832e9408","article-title":"HIV sensitivity to neutralization is determined by target and virus producer cell properties","volume":"23","author":"Mann","year":"2009","journal-title":"AIDS"},{"key":"2020081009465013200_OFV172C17","first-page":"351","article-title":"Cell-type dependent sensitivity of herpes simplex virus 1 mutants to plaque development inhibition by an anti-gD monoclonal antibody","volume":"18","author":"Mannini-Palenzona","year":"1995","journal-title":"New Microbiol"},{"key":"2020081009465013200_OFV172C18","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1128\/JVI.03690-13","article-title":"Mechanism and significance of cell type-dependent neutralization of flaviviruses","volume":"88","author":"Mukherjee","year":"2014","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C19","doi-asserted-by":"crossref","first-page":"12149","DOI":"10.1128\/JVI.01732-06","article-title":"Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein","volume":"80","author":"Oliphant","year":"2006","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C20","doi-asserted-by":"crossref","first-page":"e52327","DOI":"10.1371\/journal.pone.0052327","article-title":"Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies","volume":"7","author":"Zhai","year":"2012","journal-title":"PLoS One"},{"key":"2020081009465013200_OFV172C21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"2020081009465013200_OFV172C22","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.4049\/jimmunol.1203052","article-title":"Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection","volume":"190","author":"Boonnak","year":"2013","journal-title":"J Immunol"},{"key":"2020081009465013200_OFV172C23","doi-asserted-by":"crossref","first-page":"12479","DOI":"10.1073\/pnas.1106568108","article-title":"Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection","volume":"108","author":"Chan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020081009465013200_OFV172C24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2009.09.024","article-title":"Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype","volume":"394","author":"Rodrigo","year":"2009","journal-title":"Virology"},{"key":"2020081009465013200_OFV172C25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.antiviral.2012.09.018","article-title":"Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies","volume":"96","author":"Wu","year":"2012","journal-title":"Antiviral Res"},{"key":"2020081009465013200_OFV172C26","doi-asserted-by":"crossref","first-page":"e1003157","DOI":"10.1371\/journal.ppat.1003157","article-title":"Therapeutic efficacy of antibodies lacking Fcgamma receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies","volume":"9","author":"Williams","year":"2013","journal-title":"PLoS Pathog"},{"key":"2020081009465013200_OFV172C27","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1128\/JVI.02484-07","article-title":"Role of dendritic cells in antibody-dependent enhancement of dengue virus infection","volume":"82","author":"Boonnak","year":"2008","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C28","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.1128\/JVI.00792-06","article-title":"Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32)","volume":"80","author":"Rodrigo","year":"2006","journal-title":"J Virol"},{"key":"2020081009465013200_OFV172C29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1128\/CVI.00363-08","article-title":"Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2","volume":"16","author":"Rodrigo","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"2020081009465013200_OFV172C30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4269\/ajtmh.2009.80.61","article-title":"An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells","volume":"80","author":"Rodrigo","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020081009465013200_OFV172C31","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"2020081009465013200_OFV172C32","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1016\/j.vaccine.2015.08.008","article-title":"Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study","volume":"33","author":"Torresi","year":"2015","journal-title":"Vaccine"},{"key":"2020081009465013200_OFV172C33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020081009465013200_OFV172C34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020081009465013200_OFV172C35","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/j.vaccine.2004.03.042","article-title":"Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine","volume":"22","author":"Guy","year":"2004","journal-title":"Vaccine"},{"key":"2020081009465013200_OFV172C36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/656141","article-title":"Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers","volume":"202","author":"van Panhuis","year":"2010","journal-title":"J Infect Dis"},{"key":"2020081009465013200_OFV172C37","doi-asserted-by":"crossref","first-page":"e2274","DOI":"10.1371\/journal.pntd.0002274","article-title":"Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans","volume":"7","author":"Puschnik","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020081009465013200_OFV172C38","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/4\/ofv172\/33603004\/ofv172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/4\/ofv172\/33603004\/ofv172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T14:07:19Z","timestamp":1597068439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofv172\/2460601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofv172","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015]]},"published":{"date-parts":[[2015]]},"article-number":"ofv172"}}